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Abstract 
Schizophrenic patients at high risk for development of type 2 diabetes as a side effect of the antipsychotic 
medication This research is aimed to find out (1) the level of HbA1c and the description of hyperglycemia 
incidence, (2) the value of HOMA-β and the description of beta cell dysfunction incidence,  (3) the correlation 
between HOMA-β value with HbA1c level, (4) the duration correlation between the use of haloperidol with the 
HOMA-β value and the HbA1c level, (5) the duration correlation the use of haloperidol and the HbA1c level 
through HOMA-β value. This study was conducted at the inpatient ward of Dadi Hospital, South Sulawesi 
Province using quantitative method with cross sectional study. By using total sampling way, 64 were chosen. 
The data were then analyzed by using frequency distribution test and Spearman correlation. The result of the 
study indicates that sufferer schizophrenia at Dadi Hospital who use haloperidol have problems of 
hyperglycemia (HbA1c >5,5%). The longer the use of haloperidol the more the excelsior level of HbA1c found. 
About 4,3% hyperglycemia in use of haloperidol <1 year and 23,9% in use >1 year. The mechanism the 
hyperglycemia incidence mentioned above suffered through dysfunction of beta cell. The longer the use of 
haloperidol the lower the HOMA-β value. It reaches 28,3%  dysfunction of beta cell in use of haloperidol <1 
year and 54,3% in use >1 year.  
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The dysfunction of beta cell has relation with the duration in the use of haloperidol. The lower HOMA-β value 
level the more the excelsior level of HbA1c. The incidence of Hyperglycemia is correlated with the dysfunction 
of beta cell. 
Keywords: Antipsychotic; haloperidol; beta cell dysfunction; hyperglycemia; HOMA-β and HbA1c. 
1. Introduction 
Schizophrenic patients at high risk for development of type 2 diabetes as a side effect of the antipsychotic 
medication. Prevalence of DM reported two to three-fold higher in patients with schizophrenia who received 
antipsychotics compared with the general population [1]. In addition, there was no difference between patients 
receiving typical and atypical antipsychotics, although some opinions supporting that abnormalities in blood 
sugar may be higher with atypical than typical antipsychotic medications [2,3]. The main pathogenesis of type 2 
diabetes, the insulin disorders due to insulin resistance and impaired insulin secretion, due to dysfunction of beta 
cells (β) of the pancreas, which in turn can lead to hyperglycemia [4]. Research by Lindanmayer [5], said that 
the antipsychotic haloperidol can increase fasting blood sugar and insulin resistance through 
hyperprolactinemia, but not on resperidon. Fasting blood glucose levels also directly proportional to the duration 
of use haloperidol, where the longer used, the higher the blood glucose levels [6]. However, the different results 
obtained by Hendenmalm [7] which says that haloperidol was not associated with impaired glucose intolerance. 
The mechanism of conventional antipsychotics (haloperidol) which causes toxic is not fully understood. 
However, some experts said through an increase in weight, which is associated with insulin resistance 
mechanism. The increase in weight due to the use of antipsychotics is mediated by histamine H1 receptor, 
activating the hypothalamic AMP kinase, which can increase food intake [8]. 
Proposed different Liorente and Urrutia [9], that the complications of hyperglycemia and diabetes in the 
administration of antipsychotic, can occur without changes in body weight. Thus, the toxic effects of 
antipsychotics on pancreatic beta cells, have an important role in the pathogenesis of type 2 diabetes.  
An in vitro study suggests that, haloperidol can affect the electrical activity in pancreatic beta cells, which give a 
toxic effect on the permeability of potassium, although the mechanism is not yet known [10]. In addition, the 
chronic use of haloperidol was associated with increased incidence of impaired glucose tolerance and type 2 
diabetes, by blocking KATP channels through the inhibition of Kir 6.2 / SUR1 the KATP channel. However, the 
inhibitory effects of haloperidol on KATP not through D2 receptors [11]. Based on the above, the researcher 
was interested to study pancreatic beta cell dysfunction and hyperglycemia, in patients with schizophrenia who 
use haloperidol. 
2. Materials and Methods  
This study uses a quantitative approach to the type of cross sectional study. Data collection techniques in this 
study is the interview, physical examination, laboratory tests. To see the proportion of beta cell dysfunction and 
incidence of hyperglycemia, used test frequency distribution, and to see the relationship between the two 
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variables, Spearman correlation test. 
3. Result  
Based on this research, the data obtained respondent characteristics as shown in Table 1. 
Table 1: Characteristics of respondent data 
Variable N Mean Median  SD Min Max  
Age of respondents 
Fasting Plasma 
Glucose (FPG) 
Fasting Plasma  
Insulin (FPI) 
Homa β 
Homa β < 1 year 
Homa β > 1 year 
HbA1c 
46 
 
46 
 
46 
46 
17 
29 
46 
33,83 
 
4,74 
 
3,76 
68,86 
70,42 
67,94 
5,26 
32,5 
 
4,69 
 
2,37 
47,00 
30 
56,6 
5,00 
9,33 
 
0,44 
 
3,17 
62,88 
87,0 
45,03 
0,58 
17 
 
3,83 
 
2,00 
16,70 
16,70 
21,20 
4,00 
59 
 
5,89 
 
19,30 
365,70 
365,70 
221,40 
7,00 
HbA1c < 1 year 
HbA1c > 1 year 
17 
29 
5,06 
5,38 
5,00 
5,00 
0,43 
0,62 
4,00 
4,00 
6,00 
7,00 
Source: Primary Data 
3.1 The proportion of beta cell dysfunction and incidence of hyperglycemia by Duration Use of     
      Haloperidol (DUH) 
To determine the proportion of beta cell dysfunction and incidence of hyperglycemia in patients with 
schizophrenia who use haloperidol, used statistical test frequency distribution. From the research, the data 
obtained as shown in Table 2 and Figure 6, 7 and 8. 
3.2 Beta cell dysfunction and hyperglycemia on Usable Haloperidol 
To determine the relationship longer use haloperidol beta cell dysfunction and hyperglycemia, using Spearman 
correlation test, in accordance with Table 3. 
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Table 2:  Differences in the distribution of β cell dysfunction and hyperglycemia by long use of haloperidol 
Parameter 
Use haloperidol  
< 1  year 
(n = 17) 
Use haloperidol  
> 1 year 
(n = 29) 
OR  95% Confidence interval 
 n (%) n (%)  Lower Upper 
Beta cell dysfunction Normal 
13 (28,3) 
4 (8,7) 
25 (54,3) 
4 (8,7) 
1,923 
 
0,413 8,965 
Abnormal HbA1c 
Normal  
2 (4,3)                                
15 (32,6) 
11 (23,9) 
18 (39,1) 
4,583 
 
0,876 23,988 
Abnormal FPG 
Normal 
2 (4,3) 
15 (32,6) 
1 (2,2) 
28 (60,9) 
0,268 0,022 3,202 
       Source: Primary Data 
 
 
 
4. Discussion 
Based on the research results, it was found that the data between the duration of use of haloperidol with beta cell 
dysfunction there is no meaningful relationship, with ap value of 0.129 and a correlation coefficient of 0.227, 
which means there is a positive correlation with the strength of a weak correlation, where the longer the 
respondents using haloperidol, then the possibility of the higher beta cell dysfunction. In addition, the data 
between the duration of use of haloperidol with hyperglycemia, there is no meaningful relationship, based on 
HbA1c, with ap value of 0.063 and a correlation coefficient of 0.276, which means there is a positive correlation 
with the strength of a weak correlation, where the longer the respondents using haloperidol, then the higher the 
tendency of hyperglycemia. This can be seen in Table 3. 
Figure 6: Graph beta cell 
dysfunction by long use of 
haloperidol 
 
Figure 7: Graph abnormal 
HbA1c by long use of 
haloperidol 
Figure 8: Graph abnormal 
FPG by long use of 
haloperidol 
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Table 3: Correlation duration of the use  haloperidol with HOMA- value β, and HbA1C 
Parameter correlation coefficient (r) Probability (p) 
DUHvs HOMA-β 
DUHvs HbA1c 
HOMA-β  vs HbA1c 
0,227 
0,276 
0,288 
0,124 
0,063 
0,052 
              Source: Primary Data 
Based on the above, it can be concluded that it is in line with the existing theory that the use of antipsychotic 
haloperidol may cause hyperglycemia through toxic effects on beta cells. The results showed that, using 
haloperidol schizophrenic prone to hyperglycemia. Researchers assume, possibly through beta cell dysfunction, 
therefore the study found a decrease in the value of HOMA-β. Hyperglycemia not through insulin resistance, 
therefore none of patients who are obese, according to their Body Mass Index (BMI). 
Haloperidol can affect the electrical activity in pancreatic beta cells, which give a toxic effect on the 
permeability of potassium, although the mechanism is unknown [10]. This is consistent with the theory that, 
increased permeability of the ATP-sensitive K channels will cause potassium ions leave the beta cells (K-
efflux), thereby maintaining the membrane potential in a state of hyperpolarization, which causes depolarization 
hard going, so that Ca-channels remain closed, consequently calcium cannot get into the beta cells, so that 
stimulation of beta cells to secrete insulin exocytosis decreased. This condition will cause the cell glucose 
uptake decreased, which results in an increase in blood glucose levels [12]. 
Moreover, the tendency of beta cell dysfunction and hyperglycemia in this study, supported by studies 
conducted [11], that the chronic use of haloperidol were associated with an increased incidence of impaired 
glucose tolerance and type 2 diabetes, by blocking KATP channels through the inhibition of the Kir 6.2 / SUR1 
the KATP channel. However, the inhibitory effects of haloperidol on KATP not through D2 receptors. In 
contrast presented by Rubi Blanca [13],that the antipsychotic drugs block dopamine receptors can cause 
hyperinsulinemia, hypoglycemia, increased appetite and obesity are associated with DM. Normally, dopamine 
transporter Glut assist in cell glucose uptake. Consequently, inhibition D2R will lead to hyperglycemia, 
resulting in hyperinsulinemia. In addition, there is the theory that dopamine D2 receptors inhibit haloperidol. 
Where is the dopamine D2 receptor in beta cells play a role in the regulation of blood glucose levels, with 
inhibition of insulin secretion [14]. 
Increased secretion of dopamine can reduce ACH [15]. Thus, inhibition of dopamine D2 receptors may increase 
the ACH (adrenocorticotropin hormone), which triggers increased cortisol, so gluconeogenesis increased to ten-
fold, resulting in an increase in blood glucose levels [16]. 
Other mechanisms that explain the relationship of the use of antipsychotics with type 2 diabetes is through the 
effect on cholinergic, which can stimulate insulin secretion and activates phospholipase C, which is mediated by 
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the muscarinic M3 receptor in beta cells [17]. 
Based on theory and research data, researchers can conclude that the use of haloperidol may cause 
hyperglycemia through beta cell dysfunction, based on the cut-off point of the research Ciampelli [18] (HOMA 
β <107), where it can cause a decrease in insulin secretion. As a result, the cells decreased glucose uptake, 
resulting in hyperglycemia. No meaningful relationship between the duration of use of haloperidol with 
hyperglycemia and beta-cell dysfunction, caused by the limited number of samples, based on the attached 
sample rechecking. However, the research can provide meaning that there is a tendency to hyperglycemia and 
beta cell dysfunction, which in the study were measured by HOMA β and HbA1c examination, where the longer 
use of haloperidol, the incidence of beta cell dysfunction and hyperglycemia higher, which will eventually lead 
to type 2 diabetes. 
This is in line with the source stating that the prevalence of diabetes mellitus in patients with schizophrenia who 
received antipsychotic two to three times higher than the general public or which do not suffer from 
schizophrenia [19]. In addition, there was no difference between patients receiving typical and atypical 
antipsychotics, although some opinions supporting that abnormalities in blood sugar may be higher with 
atypical than typical antipsychotic medications [2,3]. 
Another source also stated that although the mechanism of the effects of antipsychotic drugs on the incidence of 
glucose metabolism, especially the increase in blood glucose levels, is still uncertain [20] and the amount of 
research that is still controversial, but some experts are able to formulate a mechanism that may underlying 
these events, namely through a reduction in insulin sensitivity, increased insulin resistance and toxic effects of 
antipsychotics on beta cells [5,9].  
The results of this study suggests that the tendency of beta cell dysfunction as one of the basic mechanisms of 
disease with type 2 diabetes, it occurs in individuals with longer use of haloperidol <1 year, through the toxic 
effects of antipsychotic haloperidol on beta cells, because respondents tend to decrease HOMA β. Where it is 
known that the examination HOMA β is one of the gold standard that has been widely recognized validity and 
reflect the pancreatic beta cell function accurately [21]. However, determination of cut-off point in this study 
cannot be done, because there is no control group. This becomes a limitation of the study, because there is no 
cut-off point value as a guide to determine the incidence of beta cell dysfunction. 
Moreover, the tendency of hyperglycemia by HbA1c in patients with schizophrenia who use haloperidol in this 
study, probably due to beta cell dysfunction. Where we know that the beta cell dysfunction will decrease insulin 
secretion, thus decreasing cell glucose uptake, resulting in an increase in blood glucose levels, although there is 
no significant association. This was probably due therefore, all the samples used were inpatients, where food 
supply is limited, so it will affect the process of adaptation to patients with diet and amount of food in the 
hospital. According to Goldstein [22] that, onset of beta cell dysfunction, occurs before the development of 
hyperglycemia. At the time of diagnosis of diabetes, beta cell dysfunction may be decreased to 50%, so that 
interventions for the prevention or treatment of diabetes, is more effective at the beginning of the disease, as 
early detection of beta cell dysfunction to prevent further complications of type 2 diabetes. 
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Schizophrenic patients at high risk for development of type 2 diabetes, which is not dependent on the interaction 
between genetic and environmental factors. However, it was reported that over 50% of individuals with 
schizophrenia suffer from diabetes, of which 30% had a family history of type 2 diabetes. In addition, bad 
behavior such as unhealthy diet (high fat, low fiber, lack of exercise and smoking), contribute to the 
development of diabetes, which is associated with obesity [2]. 
For this reason, according to researchers, people with schizophrenia need treatment earlier, in an effort to 
prevent damage glucose tolerance, which can lead to type 2 diabetes. Although the study, the genetic history of 
diabetes difficult to obtain, because the difficulty researchers met with families of patients. However, there are 
some patients who are found to have a genetic history of diabetes, but still showed hyperglycemia and beta-cell 
dysfunction. 
5. Conclusion 
Based on the above explanation, it can be concluded as follows: 
1. Patients with schizophrenia who use haloperidol, which is treated in RSKD Dadi, has been experiencing 
hyperglycemia (HbA1c> 5.5%). The longer the use of haloperidol higher HbA1c levels. Found 4.3% of 
hyperglycemia on the use of haloperidol <1 year, and 23.9% on the use of> 1 year. 
2. The mechanism of occurrence of hyperglycemia in patients mentioned above, through the beta cell 
dysfunction. The longer the use of haloperidol, the lower the value of HOMA-β. Found 28.3% of beta cell 
dysfunction in the use of haloperidol <1 year, and 54.3% on the use of> 1 year. Beta cell dysfunction 
associated with the use of haloperidol old. The lower the value of HOMA-β, the higher levels of HbA1c. 
Hyperglycemia that occurs, associated with beta cell dysfunction. 
Acknowledgment 
Thanks to Dr. dr. Ilhamjaya Patellongi, M. Kes and Dr. dr. Irfan Idris, M. Kes as team mentors and Nursing 
Academy of Muhammadiyah Makassar Indonesia as funders, who have helped in this study 
References 
[1] Smith, M., Hopkins, D., Peveler, R.C., Holt, R. I. G., Woodward, M., and Ismail, Kl. 2008. First-
v.Second-Generation Antipsychotics and Risk for Diabetes in Schizophrenia: Systematic Review and 
Meta-Analysis. The British Journal of Psychiatric, (Online), Vol. 192. (http://www.bjpsych.org,  
diakses 29 Maret 2010). 
[2] Gough, S. dan Peveler, R. 2004. Diabetes and Its Prevention : Pragmatic Solution for People With 
Schizophrenia. British Journal of Psychiatry, (Online), Vol. 184. No. 47. (http://bjp.rcpsych.org, 
diakses 27 April 2009). 
[3] Bushe, C. dan Holt, R. 2004. Prevalence of Diabetes and Impaired Glucose Tolerance in Patients 
148 
 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2016) Volume 25, No  1, pp 142-150 
 
 
 
With Schizophrenia. British Journal of Psychiatry, (Online), Vol. 184. No. 47. (http://bjp.rcpsych.org, 
diakses 27 April 2009). 
[4] Holt, R. I .G. 2004. Diagnosis, Epidemiology and Pathogenesis of Diabetes Mellitus : An Update 
for Psychiatrists. British Journal of Psychiatry, (Online), Vol. 184. No. 47. (http://bjp.rcpsych.org, 
diakses 27 April 2009). 
[5] Lindenmayer, J. P., Czobor, P., Volavka., J., Citrome, L., Sheitman, B., McEvoy, J. P., Cooper, T. 
B., Chakos, M. dan Lieberman, J. A. 2003. Changes in Glucose and Cholesterol Levels in Patients 
With Schizophrenia Treated With Typical or Atypical Antipsychotics. Am J Psychiatry, (Online), Vol. 
160. No. 2. (http://ajp.psychiatryonline.org, diakses pada 27 April 2009). 
[6] Erawati, R. 2009. Hubungan Penggunaan Haloperidol dan Risperidon Dengn Kadar Glukosa Darah 
Puasa Tesis tidak diterbitkan. Makassar : Program Pendidikan Dokter Spesialis I bagian Ilmu 
Kedokteran Jiwa Fakultas Kedokteran Universitas Hasanuddin. 
[7] Hendenmalm, M., 2002. Diet, Diabetes and Schizophrenia : Review and Hypothesis. British Journal 
of Psychiatry, (Online), Vol. 184. No.47. (http://bjp.rcpsych.org, diakses 27 April 2009). 
[8] Kim, S. F., Huang, A. S., Snowman, A. M., Teuscher, C., Sinder, S. H. 2007. Antipsychotic Drug-
Induces Weight Gain Mediated by Histamine H1 Receptor-Linked Activation of Hypothalamic AMP-
Kinase. The National Academy of Sciences of the USA, (Online), Vol. 104. No. 9. 
(http://www.ncbi.nml.nig. Gov. pubmed, diakses 20 April 2010). 
[9] Liorente, M. dan Urrutia, V. 2006. Psychiatric Disorders and The Metabolic Effect of Antipsychotic 
Medications. Clinical Diabetes. 24 : 18-24. 
[10] Leonard, B., Allen, P. Y., Gavin, P. R,. 2005. Action of Antipsychotic Drugs on Pancreatic Beta-
Cell Function Contrasting Effects of Clozapine and Haloperidol. Journal of Psychopharmacol, 
(Online), Vol. 19. No. 6. (http://www.ncbi.nml.nig. Gov. pubmed, diakses 18 April 2010). 
[11] Yang Shi-Bing., Proks, P., Ashcroft, FM., dan Rupnik, M. 2004. Inhibition of ATP-Sensitive 
Potassium Channels by Haloperidol. Br J Pharmacol, (Online), Vol. 143. No. 8. 
(http://ncbi.nlm.nih.gov.htm, , diakses 18 Juli 2010). 
[12] Merentek, E. 2006. Resistensi Insulin pada Diabetes Melitus Tipe 2. Cermin Dunia Kedokteran, 
(Online), (htpp://www.kalbe.com.id.htm, diakses 19 April 2010). 
[13] Rubi, B., Ljubicic, S., Pournourmohammadi, S., Carobbio, S., Armanet, M., Bartley, C., and 
Maechler, P. 2005. Dopamine D2-Like Receptors Are Expressed in Pancreatic Beta Cell and Mediate 
Inhibition of Insulin Secretion, (Online), Vol. 280. No. 44 (http://www.jbc.org,  diakses 21 Juli 2010). 
149 
 
International Journal of Sciences: Basic and Applied Research (IJSBAR) (2016) Volume 25, No  1, pp 142-150 
 
 
 
[14] Ichise, M., Harris, P. E., 2010. Imaging of β-Cell Mass anf Function,JNM, (Online), (www. 
JNM.net, diakses 28 Juli 2010). 
[15] Mergenhagen, K. A. 2008. Delirium In The Elderly : Medication, Causes, and Treatment. 
(Online), (htpp://www.uspharmacist.com.htm, diakses  10 April 2010). 
[16] Guyton, A. C. dan Hall, J. E. 2008. Text Book of Medical Physiology. Edisi II. Elsevier Saunders : 
Philadelphia. 
[17] Johnson, D. E., Yamazaki, H., Ward, K. M., Schmidt, A. W., Lebel, W. S., Treadway, J. L., 
Gibbs, E. M., Zawalich, W. S., and Rollema, H. 2005. Inhibitory Effects og Antipsychotic on 
Carbachol-Enhanced Insulin Secretion from Perifused Rat Islets.,JNM, (Online), (www. JNM.net, 
diakses 28 Juli 2010). 
[18] Ciampelli , M., Leoni, F., Cucinelli, F., Mancuso, S., Panunsi, S., Gaetano, A. D., and Lanzone, A. 
2005. Assessment of Insulin Sensitivity from Measurement in The Fasting State and During an 
Menopausal Patients.The Journal of Clinical Endocrinology & Metabolism. (Online), Vol. 90 No. 3 
(http://jcem.endojournals.org//subscriptions/ , diakses tanggal 28 Juli 2010). 
[19] Smith, M., Hopkins, D., Peveler, R.C., Holt, R. I. G., Woodward, M., and Ismail, KI. 2008. First-
v.Second-Generation Antiphsychotics and Risk for Diabetes in Schizophrenia: Systematic Review and 
Meta-Analysis. The British Journal  of Psychiatric,  (Online), Vol. 192. (http://www.bjpsych.org, 
diakses 29 Maret 2010). 
[20] Expert Group. 2004. Schizophrenia and Diabetes 2003, Expert Consensus Meeting, Dublin, 3-4 
October 2003 : Consensus Summary. British Journal of Psychiatry, (Online), Vol.184. No. 47. 
(http://bjp.rcpsych.org, diakses 27 April 2009). 
[21] Song, Y., Manson, J.E., Tinker, L., Howard, B.V., Kuller, R.H., Nathan, L., Rifai, N., Liu, S. 
2007. Insulin Sensitivity and Insulin Secretion Determined by HOMA and Risk of Diabetes in a 
Multiethnic Cohort of Woman : The Womans Helath Inisiative Observational Study. J Diabetes Care, 
(Online), Vol. 30. No. 7. (http://www.ncbi.nlm.nih,  diakses 29 Maret 2010). 
[22] Goldstein, B.J. 2002. Insulin Resistance as the core Defect in Type 2 Diabetes Mellitus.Am J 
Cardiol, (Online), Volume. 90.. (http://AmJ.org, diakses 10 Agustus 2010). 
150 
 
